,Canonical_Smiles,drug_name,drug_type,Label
0,NC(=O)N1c2ccccc2C=Cc2ccccc21,Carbamazepine,P450_HFLA-Substrate,negative
1,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminoglutethimide,-,negative
2,CCn1ncnc1COc1nn2c(-c3ccccc3F)nnc2cc1C(C)(C)C,TPA_023,3A4-Substrate,negative
3,C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1,bupropion,2E1-Substrate,negative
4,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
5,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,cerivastatin,3A4-Substrate,negative
6,COc1c(N2CCN[C@@H](C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Gatifloxacin,-,negative
7,OCC(CO)N[C@H]1C[C@@](O)(CO)[C@H](O)[C@@H](O)[C@@H]1O,Voglibose,2E1-Inducer,negative
8,CN1CCN(C(=O)O[C@@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,Zopiclone,2E1-Substrate,negative
9,CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12,Mepacrine,Methyltransferase-Inhibitor,negative
10,CC(=O)C1CCC2C3CCC4CC(C)(O)CCC4(C)C3CCC12C,Ganaxolone,-,negative
11,COC(=O)c1cc(OC)c2c(c1-c1c(C(=O)OC)cc(OC)c3c1OCO3)OCO2,DDB_aka_BDD,2C9-Substrate,negative
12,CCOc1ccc2nc3ccc(=O)cc-3oc2c1,7_ethoxy_resorufin,1A2-Substrate,negative
13,C1CNCCN1,Piperazine,2D6-Substrate,negative
14,Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,Sertaconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
15,CC(C)COC[C@H](CN(Cc1ccccc1)c1ccccc1)N1CCCC1,Bepridil,2D6-Substrate,negative
16,O=O,Oxygen,Solute_carrier_family_12_member_2-Inducer,negative
17,CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminogluthetimide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
18,CCO[C@H]1O[C@@H]2OC3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,beta_arteether,3A4-Substrate,negative
19,CN[C@@H](C)Cc1ccccc1,Metamfetamine,2D6-Substrate,negative
20,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,Idarubicin,2D6-Inhibitor,negative
21,O=C(NC1CCSC2CCCC(C(=O)O)N2C1=O)C(S)Cc1ccccc1,Omapatrilat,-,negative
22,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,clarithromycin,3A4-Substrate,negative
23,CCC(=O)C1(c2cccc(O)c2)CCN(C)CC1,Ketobemidone,2B6-Substrate,negative
24,Clc1cccc(N2CCNCC2)c1,m-Chlorophenylpiperazine,2D6-Substrate,negative
25,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,Quazepam,2C19-Substrate,negative
26,CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12,Alpidem,-,negative
27,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,Amoxicillin,Solute_carrier_family_22_member_6-Substrate,negative
28,c1ccc([C@H]2CN3CCSC3=N2)cc1,Levamisole,GST-Inducer,negative
29,Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,Cefazolin,Solute_carrier_family_22_member_6-Substrate,negative
30,CCCC(=O)Nc1ccc(OC[C@@H](O)CNC(C)C)c(C(C)=O)c1,Acebutolol,2D6-Inhibitor,negative
31,N[C@H]1C[C@@H]1c1ccccc1,Tranylcypromine,2E1-Inhibitor,negative
32,O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1,Anagrelide,1A2-Substrate,negative
33,Clc1ccc([C@@H](Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1,Tioconazole,19A-Inhibitor,negative
34,O=C([O-])O,Sodium Bicarbonate,Electroneutral_sodium_bicarbonate_exchanger_1-Substrate,negative
35,CN(C)CCC=C1c2ccccc2COc2ccccc21,Doxepin,GST-Inhibitor,negative
36,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,hesperetin,1A2-Substrate,negative
37,CCN(CC)C(=O)NC1CC2c3cccc4[nH]cc(c34)CC2N(C)C1,Terguride,2D6-Substrate,negative
38,CCCSP(=S)(OCC)Oc1ccc(SC)cc1,sulprofos,2D6-Substrate,negative
39,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,Dihydroergotamine,-,negative
40,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CC,Etoperidone,2D6-Substrate,negative
41,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,Methylphenidate,-,negative
42,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,Chlorpropamide,2C19-Substrate,negative
43,NC(N)=Nc1nc(CSCCN=CNS(=O)(=O)c2ccc(Br)cc2)cs1,Ebrotidine,-,negative
44,CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,Ipriflavone,2E1-Inducer,negative
45,N=C(N)N1CCc2ccccc2C1,Debrisoquine,2D6-Substrate,negative
46,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Dihydrocodeine,2D6-Substrate,negative
47,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,Quinidine,1A1-Inhibitor,positive
48,C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)C(=NOCC(=O)O)c3csc(N)n3)[C@H]2SC1,Cefixime,Solute_carrier_family_15_member_1-Substrate,negative
49,Nc1ccccc1,Aniline,-,negative
50,C/C=C/C,trans_2_butene,2E1-Substrate,negative
51,COc1ccc(CCN(C)CCC[C@](C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC,Gallopamil,-,negative
52,CN(CCCC(=O)c1cccnc1)N=O,NNK,2E1-Substrate,negative
53,COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O,Ubidecarenone,Methyltransferase-Substrate,negative
54,Cc1cc(O)cc(C)c1Cl,Chloroxylenol,2E1-Substrate,negative
55,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1,Cefadroxil,Solute_carrier_family_15_member_2-Substrate,negative
56,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,flunarizine,2D6-Substrate,negative
57,CCOP(=O)(OCC)Oc1ccc([N+](=O)[O-])cc1,Paraoxon,2E1-Substrate,negative
58,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,ursodeoxycholic_acid,3A4-Substrate,negative
59,CCOC(=O)c1cncn1[C@@H](C)c1ccccc1,Etomidate,19A-Inhibitor,negative
60,C#CCN(C)Cc1ccccc1,Pargyline,2E1-Inhibitor,negative
61,CCCCCCNC(=N)NC(=N)N.Cl,Polihexanide,GST-Inhibitor,negative
62,C=CCc1ccc(OC)c(OC)c1,methyl_eugenol,2D6-Substrate,negative
63,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Kanamycin,Solute_carrier_family_12_member_2-Inhibitor,negative
64,Cc1ncc(COP(=O)(O)O)c(C=O)c1O,Pyridoxal Phosphate,SUL-Inhibitor,negative
65,c1ccc2cc(COC3CCNCC3)ccc2c1,Litoxetine,-,negative
66,CSCC[C@H](N)C(=O)O,Methionine,GST-Inducer,negative
67,CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@@]21C,Promegestone,SUL-Inducer,negative
68,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,Tobramycin,N_acetyltransferase-Substrate,negative
69,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)C(=O)C1=O,Cefoperazone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
70,CCC1(C)CC(OC(=O)CSc2n[nH]c(N)n2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O,Azamulin,-,negative
71,O[C@@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1,Nebivolol,2D6-Substrate,negative
72,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,Levacetylmethadol,19A-Substrate,negative
73,O=C1C=C2CN(Cc3ccccc3Cl)CCC2S1,2_oxo_ticlopidine,2D6-Substrate,negative
74,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,thalidomide,2C19-Substrate,negative
75,COc1ccc2c(c1)c(CC(=O)NCCc1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,indomethacin_phenethylamide,2D6-Substrate,negative
76,Cc1nc2c([nH]1)c(=O)n(C)c(=O)n2CC1CCCCC1,BRN_4201400,1A2-Substrate,negative
77,CCC1(CC)C(=O)NC(=O)N(C)C1=O,Metharbital,1B1-Inducer,negative
78,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Everolimus,-,negative
79,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O,Estriol,1A1-Inhibitor,positive
80,Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,Thiamine (vit B1),P450_HP-Inducer,negative
81,CC[C@H](C(N)=O)N1CCCC1=O,Levetiracetam,GST-Inducer,negative
82,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,Spironolactone,-,negative
83,CNC[C@H](O)c1ccc(O)c(O)c1,Epinephrine,SUL-Substrate,negative
84,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Sufentanil,-,negative
85,C[C@@H](N)[C@@H](O)c1ccccc1,Phenylpropanolamine,1A2-Inhibitor,negative
86,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O,androstenedione,3A4-Substrate,negative
87,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,Proguanil,2E1-Substrate,negative
88,CCc1cccc2cc([C@H](O)CNC(C)(C)C)oc12,bufuralol_R,2D6-Substrate,negative
89,CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@@H](CO)c1ccccc1)C2,Atropine,1A2-Inhibitor,negative
90,FC(F)O[C@@H](Cl)C(F)(F)F,Isoflurane,2E1-Substrate,negative
91,COc1ccc2[nH]cc(CCN(C(C)C)C(C)C)c2c1,foxy,2D6-Substrate,negative
92,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,Ribavirin,Solute_carrier_family_28_member_3-Substrate,negative
93,Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,Febuxostat,UGT-Substrate,negative
94,COc1ccccc1OCCNC[C@H](O)COc1cccc2[nH]c3ccccc3c12,carvedilol_S,2D6-Substrate,negative
95,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O,Bezafibrate,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
96,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Gemcitabine,Multidrug_resistance_associated_protein_5-Inducer,negative
97,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisone,-,negative
98,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,Nelfinavir,P450_HFLA-Inhibitor,negative
99,O=S(Cc1ccccn1)c1nc2ccccc2[nH]1,Timoprazole,-,negative
100,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,Oxaprozin,2C9-Substrate,negative
101,Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,Dapsone,CP2CI-Substrate,negative
102,CCN(CC)C(=O)C1(c2ccccc2)CC1CN,Milnacipran,-,negative
103,N.N.O=C1O[Pt]OC(=O)C12CCC2,Carboplatin,3A4-Inducer,negative
104,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@H]1c1ccccc1Cl,Amlodipine,1A1-Inhibitor,positive
105,CCNc1nc(NC(C)(C)C)nc(SC)n1,terbutryn,2C19-Substrate,negative
106,O=C(O)CC(O)(CC(=O)O)C(=O)[O-],Sodium Citrate,SUL-Inhibitor,negative
107,C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,Masoprocol,Arachidonic_acid_epoxygenase-Inhibitor,negative
108,Nc1c2c(nc3ccccc13)CCCC2,Tacrine,GST-Substrate,negative
109,CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,Delapril,-,negative
110,COc1cc2c(cc1OC)C(=O)[C@H](CC1CCN(Cc3ccccc3)CC1)C2,Donepezil,2D6-Substrate,negative
111,CNC(=NC#N)NCCSCc1nc[nH]c1C,Cimetidine,2E1-Inhibitor,negative
112,NC(=O)NO,Hydroxycarbamide,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
113,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc21,Valaciclovir,Solute_carrier_family_15_member_2-Substrate,negative
114,Cc1ccc2c(=O)c3cccc(CC(=O)O)c3oc2c1C,DMXAA,1A2-Substrate,negative
115,CO[C@@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@]3(CO3)C[C@H](C)[C@H](O[C@H]3O[C@@H](C)C[C@@H](N(C)C)[C@H]3O)[C@H]2C)O[C@@H](C)[C@H]1O,Oleandomycin,UGT-Substrate,negative
116,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,Artemisinin,GST-Inhibitor,negative
117,CN1C2CCC1CC(OC(=O)c1c[nH]c3ccccc13)C2,Tropisetron,2D6-Substrate,negative
118,CCOC(=O)n1ccn(C)c1=S,Carbimazole,-,negative
119,O=C1CN(N=Cc2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,Dantrolene,1A1-Inhibitor,positive
120,CCOP(=S)(OCC)Oc1cc(C)nc(C(C)C)n1,diazinion,2E1-Substrate,negative
121,CN1CCN(CCCCN2C(=O)CN(N=Cc3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,Azimilide,-,negative
122,C[C@@H](NC(=Nc1ccncc1)NC#N)C(C)(C)C,Pinacidil,2D6-Substrate,negative
123,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,Zafirlukast,2E1-Inhibitor,negative
124,COc1cc([C@H]2c3cc4c(cc3C[C@@H]3COC(=O)[C@H]32)OCO4)cc(OC)c1OC,Podophyllotoxin,2C19-Substrate,negative
125,c1ccc2[nH]ccc2c1,indole,2E1-Substrate,negative
126,C[C@@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1,Labetalol,2D6-Inhibitor,negative
127,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(C(C)C)cccc2C(C)C)c(C(C)C)c1,Avasimibe,-,negative
128,CC(=O)N=c1sc(S(N)(=O)=O)nn1C,Methazolamide,2E1-Inhibitor,negative
129,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,Tienilic Acid,GST-Inhibitor,negative
130,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,Amodiaquine,2D6-Inhibitor,negative
131,C[C@@H](O)[C@@H]1NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,Octreotide,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
132,Cc1ccnc(NC(=O)[C@H](C)c2cccc(C(=O)c3ccccc3)c2)c1,Oxatomide,2D6-Inhibitor,negative
133,N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O,Oxitriptan,Proton_coupled_amino_acid_transporter_1-Inhibitor,negative
134,COc1ccc2c3c1O[C@H]1C(OC(C)=O)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341,Thebacon,2D6-Substrate,negative
135,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,Daunorubicin,-,negative
136,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,Amsacrine,2D6-Substrate,negative
137,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,chlorpyrifos,2D6-Substrate,negative
138,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Cholic Acid,SUL-Substrate,negative
139,Cc1ncc([N+](=O)[O-])n1C[C@H](O)CCl,Ornidazole,P450_HFLA-Substrate,negative
140,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
141,c1ccc2c(c1)Sc1ccccc1N2C[C@H]1CN2CCC1CC2,Mequitazine,2D6-Substrate,negative
142,O=[S@](Cc1cc(OCC2CC2)ccn1)c1nc2ccc(F)cc2[nH]1,H_259_31_R,2C19-Substrate,negative
143,NNCCc1ccccc1,Phenelzine,P450_HFLA-Inhibitor,negative
144,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,Levofloxacin,-,negative
145,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C,Physostigmine,Methyltransferase-Inhibitor,negative
146,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Amprenavir,2D6-Substrate,negative
147,NCC(=O)CCC(=O)O,Aminolevulinic Acid,Solute_carrier_family_15_member_2-Substrate,negative
148,Cc1ccc(C(=O)[C@H](C)CN2CCCCC2)cc1,Tolperisone,2D6-Substrate,negative
149,O=C1C(CCSc2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,sulfinpyrazone_sulfide,2C9-Substrate,negative
150,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,Ranitidine,2D6-Substrate,negative
151,CC[N+](C)(CC)CCc1c(C)c2ccc(OC)cc2oc1=O,AMMC,2D6-Substrate,negative
152,C#CCN(C)[C@H](C)Cc1ccccc1,Selegiline,2E1-Inhibitor,negative
153,CN(CC=CC#CC(C)(C)C)Cc1cccc2ccccc12,Terbinafine,19A-Inhibitor,negative
154,C#C[C@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)CC[C@H]4[C@H]3C(=C)C[C@]21CC,Etonogestrel,-,negative
155,N[C@@H]1[C@@H](O)O[C@@H](CO)[C@H](O)[C@H]1O,Glucosamine,2E1-Substrate,negative
156,COc1ccc(OC)c([C@@H](O)[C@@H](C)N)c1,Methoxamine,Solute_carrier_family_12_member_2-Inducer,negative
157,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,Androstanolone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Substrate,negative
158,COc1ccc(CN2CCNCC2)c(OC)c1OC,Trimetazidine,-,negative
159,CC(C)n1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,fluvastatin,2D6-Substrate,negative
160,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,Perphenazine,CP2CI-Substrate,negative
161,CC(C)(C(=O)O)c1ccc([C@@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,Fexofenadine,2D6-Inhibitor,negative
162,CC[Hg]Sc1ccccc1C(=O)[O-],Thiomersal,GST-Inhibitor,negative
163,COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,omeprazole_S,2C19-Substrate,negative
164,COSc1cn(C)c2cc(F)ccc2c1=O,Flosequinan,-,negative
165,Cc1ccc(C)cc1,xylene_para,2E1-Substrate,negative
166,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C,Pentazocine,2D6-Substrate,negative
167,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCN(CCO)CC1,Tiaramide,-,negative
168,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Hydroxyprogesterone,Steroid_21_hydroxylase_21_OHase-Substrate,negative
169,CCCCc1nc(Cl)c(C=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,losartan_carboxaldehyde_EXP_3179,2C9-Substrate,negative
170,N#Cc1ccc(C2CCCc3cncn32)cc1,Fadrozole,-,negative
171,COc1cc(-c2cc3c(c(=O)o2)C[C@]2(O)[C@](C)(CC[C@@]4(O)C(C)(C)C=CC(=O)[C@@]42C)O3)cc2c1OCO2,territrem_A,2D6-Substrate,negative
172,O=C(Cc1cccs1)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12,Cefaloridine,2C8-Substrate,negative
173,CCOc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,Ethylmorphine,P450_HFLA-Substrate,negative
174,O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,Sulfinpyrazone,-,negative
175,OO,Hydrogen Peroxide,GST-Inhibitor,negative
176,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)[C@@H]1c1cccc([N+](=O)[O-])c1,Manidipine,2D6-Inhibitor,negative
177,C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@@]43C)[C@@H]1CCC2=O,Formestane,19A-Inhibitor,negative
178,CN1CCN(C2=Nc3cc(F)ccc3Cc3ccccc32)CC1,Fluperlapine,2D6-Substrate,negative
179,CC(C)CC(O)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1,bortezomib_M1_M2,2C19-Substrate,negative
180,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,Fosphenytoin,-,negative
181,NCCc1ccc(O)c(O)c1,Dopamine,19A-Inhibitor,negative
182,C#CCC12CCC(=O)C=C1CCC1C3CCC(=O)C3(C)CCC12,Plomestane,-,negative
183,Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C,Tiagabine,2D6-Substrate,negative
184,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,Clindamycin,-,negative
185,C[C@@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@H]2O,Estradiol,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
186,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,Finasteride,GST-Inhibitor,negative
187,COc1cc(N[C@H](C)CCCN)c2ncccc2c1,Primaquine,GST-Inhibitor,negative
188,CC(C)(C)NC[C@H](O)COc1cccc2c1CCC(=O)N2,Carteolol,2D6-Inhibitor,negative
189,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,Paclitaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
190,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C,Metamizole Sodium,GST-Inducer,negative
191,CC(C)CCC[C@@H](C)[C@@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3C[C@H](O)[C@]12C,5beta_cholestane_3alpha_7alpha_12alpha_triol,2C19-Substrate,negative
192,CC(=O)Oc1ccccc1C(=O)O,Acetylsalicylic Acid,GST-Inducer,negative
193,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,Lamivudine,Solute_carrier_family_22_member_1-Substrate,negative
194,C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2,Memantine,2D6-Inhibitor,negative
195,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Clopidogrel,-,negative
196,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,Triazolam,P450_HFLA-Substrate,negative
197,C=CC1=C(C)c2cc3[n-]c(cc4nc(cc5[n-]c(cc1n2)c(C)c5C=C)C(C)=C4CCC(=O)O)c(CCC(=O)O)c3C.O[Fe+2],Hematin,GST-Inhibitor,negative
198,NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21,Eslicarbazepine,UGT-Substrate,negative
199,CCC(=O)O[C@@H](O[P@@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,Fosinopril,Solute_carrier_family_15_member_2-Substrate,negative
200,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(=O)O,Unoproston,Solute_carrier_organic_anion_transporter_family_member_1A2-Substrate,negative
201,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,Tolbutamide,CP2CI-Substrate,negative
202,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifaximin,3A4-Inducer,negative
203,N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,Chlorhexidine,Methyltransferase-Inhibitor,negative
204,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
205,C[C@@H]1Cc2c(Cl)cc(C(=O)N[C@@H](Cc3ccccc3)C(=O)O)c(O)c2C(=O)O1,ochratoxin_A,2C9-Substrate,negative
206,CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,Acetylcarnitine,Solute_carrier_family_22_member_5-Substrate,negative
207,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,Loratadine,2D6-Inhibitor,negative
208,CC(C)NCCCOc1cccc2ccccc12,deshydroxy_propranolol,2D6-Substrate,negative
209,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(C=NNO)cc1)C1CCCCC1,Ximelagatran,2C9-Substrate,negative
210,COc1ccc(OC)c([C@H](O)CNC(=O)CN)c1,Midodrine,2D6-Inhibitor,negative
211,C=CCc1ccccc1OC[C@@H](O)CNC(C)C,Alprenolol,2D6-Substrate,negative
212,CCN(C)C=O,N_methyl_ethyl_formamide,2E1-Substrate,negative
213,Cc1ncc(CO)c(CO)c1O,Pyridoxine (vit B6),Methyltransferase-Inhibitor,negative
214,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,Ursodeoxycholic Acid,2E1-Inducer,negative
215,COCC[C@H]1CC2CN3CCc4c([nH]c5ccccc45)[C@](C(=O)OC)(C2)C13,18_methoxy_coronaridine,2D6-Substrate,negative
216,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,Cyproterone,19A-Inhibitor,negative
217,O=C(c1cccs1)c1ccc(OCCCO)c(Cl)c1Cl,tienilic_acid_deriv_3,2C19-Substrate,negative
218,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,Reserpine,-,negative
219,CCC1NC(=O)C(NC(=O)c2ncccc2O)C(C)OC(=O)C(c2ccccc2)NC(=O)C2CC(=O)C(CSC3CN4CCC3CC4)CN2C(=O)C(Cc2ccc(N(C)C)cc2)N(C)C(=O)C2CCCN2C1=O,Quinupristin,-,negative
220,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,Oseltamivir,Solute_carrier_family_15_member_1-Substrate,negative
221,CN(C)c1ccc(C2CC3(C)C(CCC3(O)CCCO)C3CCC4=CC(=O)CCC4=C23)cc1,Onapristone,-,negative
222,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,Colecalciferol,1A1-Inhibitor,positive
223,Fc1ccc(C(c2ccc(F)cc2)N2CCN(CC=Cc3ccccc3)CC2)cc1,Flunarizine,GST-Inducer,negative
224,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,Cortisol,-,negative
225,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1c1ccccc1[N+](=O)[O-],Aranidipine,-,negative
226,CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1,Fesoterodine,2D6-Substrate,negative
227,CCNc1nc(Cl)nc(NC(C)C)n1,atrazine,2E1-Substrate,negative
228,Cc1cn[nH]c1,Fomepizole,2E1-Inhibitor,negative
229,Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1,Zalcitabine,P450_HFLA-Substrate,negative
230,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,Naloxone,2C8-Substrate,negative
231,FCOC(C(F)(F)F)C(F)(F)F,Sevoflurane,2E1-Substrate,negative
232,CN(C)C(=O)Oc1ccc[n+](C)c1,Pyridostigmine,3A4-Inducer,negative
233,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1,Prazepam,3A4-Substrate,negative
234,COc1ccc(C(=O)[C@@H](C)N2CCCC2)cc1,MOPPP_R,2D6-Substrate,negative
235,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)[C@H]1c1cccc([N+](=O)[O-])c1,Lercanidipine,P450_HFLA-Substrate,negative
236,Nc1nc2c(ncn2COCCO)c(=O)[nH]1,Aciclovir,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
237,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1,Sulfadimethoxine,-,negative
238,COC(=O)[C@H](c1ccccc1Cl)N1CCC2SC(=O)C=C2C1,2_oxo_clopidogrel,2D6-Substrate,negative
239,Cc1nc2c([nH]1)c(=O)n(C)c(=O)n2Cc1ccco1,Furafylline,-,negative
240,CON=CC1=CCCN(C)C1,Milameline,2D6-Substrate,negative
241,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,Raloxifene,19A-Inhibitor,negative
242,O=C(O)c1ccccc1O,Salicylic Acid,2E1-Inducer,negative
243,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,Ascorbic Acid (vit C),GST-Inhibitor,negative
244,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,Mizolastine,2E1-Inhibitor,negative
245,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,simvastatin_hydroxy_acid,2C8-Substrate,negative
246,Cc1c[nH]c2ccccc12,3_methylindole,2E1-Substrate,negative
247,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,Clemastine,2D6-Inhibitor,negative
248,O=C(O[C@@H]1C[C@@H]2C[C@@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12,Dolasetron,2D6-Substrate,negative
249,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,Sertindole,2D6-Substrate,negative
250,C=CCc1cc(OC)c2c(c1)OCO2,myristicin,1A2-Substrate,negative
251,CN1CCCC[C@H]1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21,Mesoridazine,2D6-Substrate,negative
252,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,Piroxicam,-,negative
253,NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1,Sultiame,N_acetyltransferase-Inducer,negative
254,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
255,CC12CCC(=O)C=C1C1CC1C1C2CCC2(C)C1C1CC1C21CCC(=O)O1,Drospirenone,-,negative
256,NC(=O)c1cn(Cc2c(F)cccc2F)nn1,Rufinamide,3A4-Inducer,negative
257,C=CC(C)(O)CCC=C(C)C,linalool,2D6-Substrate,negative
258,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,Dirithromycin,-,negative
259,CN1C2CCC1CC(OC(c1ccccc1)c1ccccc1)C2,Benzatropine,2D6-Substrate,negative
260,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,Clozapine,2E1-Inhibitor,negative
261,CC[C@H](Cc1ccc2c(c1)OCO2)NC,MBDB,2D6-Substrate,negative
262,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=C[C@H](O)C[C@@H](O)CC(=O)O,Rosuvastatin,Sodiumbile_acid_cotransporter-Substrate,negative
263,Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,Lopinavir,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
264,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,all_trans_retinal,2D6-Substrate,negative
265,CC(C)NC[C@H](O)COc1cccc2ccccc12,propranolol_S,2D6-Substrate,negative
266,C[C@H]1[C@@H]2CC[C@H](C)[C@H]3CC[C@]4(C)OO[C@]23[C@@H](O[C@@H]1OC(=O)CCC(=O)O)O4,Artesunate,-,negative
267,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,Flunitrazepam,-,negative
268,CN(C)N=O,NN_dimethyl_nitrosoamine,2E1-Substrate,negative
269,CC=CCC(C)C(=O)C1C(=O)NC(C(C)C)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,Valspodar,-,negative
270,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,Tretinoin,Solute_carrier_family_28_member_3-Inducer,negative
271,CN1CCCN=C1C=Cc1cccs1,Pyrantel,2D6-Substrate,negative
272,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,Phenylbutazone,-,negative
273,N=O,Nitric Oxide,GST-Inducer,negative
274,Oc1c(I)cc(Cl)c2cccnc12,Clioquinol,SUL-Inhibitor,negative
275,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,Palonosetron,2D6-Substrate,negative
276,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,Azathioprine,Methyltransferase-Substrate,negative
277,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1,Dexfenfluramine,2E1-Inhibitor,negative
278,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1,Benoxaprofen,1A2-Inducer,negative
279,CC(C)(C)c1cc(CC2SCNC2=O)cc(C(C)(C)C)c1O,Tazofelone,-,negative
280,COc1c(C)c2c(c(O)c1CC=C(C)CCC(=O)O)C(=O)OC2,Mycophenolic Acid,Solute_carrier_family_22_member_6-Substrate,negative
281,CCc1ccc([C@@H](C)CCc2ccc([N+](C)(C)C)cc2)cc1,Colestyramine,Sodiumbile_acid_cotransporter-Inducer,negative
282,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1,Reboxetine,2D6-Inducer,negative
283,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2CC[C@@H]1N2C,Cocaine,GST-Inducer,negative
284,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,Celecoxib,SUL-Inhibitor,negative
285,C=CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_10,3A4-Substrate,negative
286,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cinnarizine,2D6-Substrate,negative
287,CN[C@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,Frovatriptan,-,negative
288,CN(C)CCC=C1c2ccccc2COc2ccc(CC(=O)O)cc21,Olopatadine,-,negative
289,COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,Trabectedin,2E1-Substrate,negative
290,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1,Tecastemizole,-,negative
291,CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1,Budipine,2D6-Inhibitor,negative
292,OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O,Inosine,Solute_carrier_family_28_member_3-Inhibitor,negative
293,Nc1nc(NC2CC2)c2ncn([C@@H]3C=C[C@H](CO)C3)c2n1,Abacavir,-,negative
294,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O,Famciclovir,3A4-Substrate,negative
295,O=C(O)c1cccnc1,Nicotinic Acid,2D6-Inhibitor,negative
296,C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C,Tibolone,19A-Inhibitor,negative
297,CC(C)N=C(N)N=C(N)Nc1ccc(Cl)c(Cl)c1,Chlorproguanil,-,negative
298,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,Quercetin,-,negative
299,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,all_trans_retinoic_acid,2C9-Substrate,negative
300,Cc1ccccc1C,xylene_ortho,2E1-Substrate,negative
301,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1,Alfentanil,P450_HFLA-Substrate,negative
302,CC(N)Cc1ccc2c(c1)OCO2,MDA_tenamfetamine,2D6-Substrate,negative
303,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21,Flurazepam,2E1-Inhibitor,negative
304,Nc1nc2cc(Cl)ccc2o1,Zoxazolamine,-,negative
305,CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)n2C1,licofelone_M1,2C8-Substrate,negative
306,O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,Niclosamide,-,negative
307,CCOc1ccc2cc(C#N)c(=O)oc2c1,3_cyano_7_ethoxycoumarin,2E1-Substrate,negative
308,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(C=NN5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifampicin,4A11-Inducer,negative
309,O=c1ccc2ccccc2o1,Coumarin,-,negative
310,O=P([O-])([O-])O,[32P]Natriumphosphat,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Substrate,negative
311,CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_4,3A4-Substrate,negative
312,O=C(O)COc1ccc(C(=O)c2cccs2)cc1,suprofen_desmethyl,2C9-Substrate,negative
313,COc1cc(CNC(=O)CCCCC=CC(C)C)ccc1O,Capsaicin,2E1-Substrate,negative
314,CCN(CC)C(=O)C(C#N)=Cc1cc(O)c(O)c([N+](=O)[O-])c1,Entacapone,2E1-Inhibitor,negative
315,CCC1(C2=CCCCC2)C(=O)NC(=O)NC1=O,Cyclobarbital,HLp2-Inducer,negative
316,CNC(=O)Oc1cc(C)c(SC)c(C)c1,Methiocarb,2D6-Substrate,negative
317,COc1ccc2cc(CCC(C)=O)ccc2c1,nabumetone,2E1-Substrate,negative
318,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,Prazosin,Solute_carrier_family_22_member_1-Inhibitor,negative
319,CCCN1CCC[C@@H](c2cccc(S(C)(=O)=O)c2)C1,OSU_6162,2D6-Substrate,negative
320,CCNc1ncn(Cc2ccc(OC)c(OC3CCCC3)c2)c2nc(C(C)C)nc1-2,V_11294,2D6-Substrate,negative
321,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,Trifluoperazine,-,negative
322,COc1ccc(-c2nc3ccc(C4=NNC(=O)CC4C)cc3[nH]2)cc1,Pimobendan,-,negative
323,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Mometasone,2C8-Inhibitor,negative
324,CCCCN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C,bupivacaine_R,2D6-Substrate,negative
325,CN1CCN(CCCN2c3ccccc3Sc3ccccc32)CC1,Perazine,2E1-Substrate,negative
326,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,barnidipine,2D6-Substrate,negative
327,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,Trimetrexate,-,negative
328,C=C(C)C1CO1,isoprene_epoxide_2,2E1-Substrate,negative
329,C[C@@H](O[C@@H]1OCCN(Cc2nc(=O)[nH][nH]2)[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,Aprepitant,P450_HFLA-Substrate,negative
330,CCc1cccc2cc(C(O)CNC(C)(C)C)oc12,Bufuralol,2D6-Substrate,negative
331,CCN(CC)CCOC(=O)c1ccc(N)cc1,Procaine,Methyltransferase-Inhibitor,negative
332,CCNc1nc(Cl)nc(NC(C)(C)C)n1,terbutylazine,2C19-Substrate,negative
333,NN=c1[nH]ncc2ccccc12,Hydralazine,Methyltransferase-Inducer,negative
334,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Betamethason,19A-Inducer,negative
335,CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(O)O[C@H]2[C@H]1OC(=O)CCC,Bucladesine,19A-Inducer,negative
336,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,Vardenafil,HLp2-Substrate,negative
337,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)C=Cc2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,Rescinnamine,Multidrug_resistance_protein_1-Inducer,negative
338,ClC=C(Cl)Cl,Trichloroethylene,2E1-Substrate,negative
339,CN1CCN2c3ccccc3Cc3ccccc3[C@H]2C1,Mianserin,2D6-Substrate,negative
340,CCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_ethylamphetamine,2D6-Substrate,negative
341,NN=O,Nitrosamine,-,negative
342,COc1ccc2c3c([nH]c2c1)C(C)=NCC3,harmaline,2D6-Substrate,negative
343,CN[C@@H](C)[C@@H](O)c1ccccc1,Pseudoephedrine,SUL-Substrate,negative
344,CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,Etizolam,2C19-Substrate,negative
345,COc1ccccc1OC[C@H]1CNC(=O)O1,Mephenoxalone,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
346,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@@H]13,Eplerenone,P450_HFLA-Substrate,negative
347,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,Moclobemide,Methyltransferase-Inhibitor,negative
348,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,Chloramphenicol,-,negative
349,NC(=O)c1ccccc1O,Salicylamide,1A1-Inhibitor,positive
350,C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,Exemestane,19A-Inhibitor,negative
351,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,Parecoxib,2D6-Inhibitor,negative
352,COc1ccc([C@@H](CN(C)C)C2(O)CCCCC2)cc1,Venlafaxine,2D6-Inhibitor,negative
353,CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,Hydrocortisone Aceponate,3A4-Substrate,negative
354,Cc1cccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1,Meclozin,1A2-Inhibitor,negative
355,Cc1cc(=O)oc2cc(O)ccc12,Hymecromone,UGT-Inhibitor,negative
356,CN(C)CCC=C1c2ccccc2Sc2ccc(Cl)cc21,Chlorprothixene,3A4-Substrate,negative
357,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,Mefloquine,19A-Inhibitor,negative
358,CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(C(C)=O)c1,Celiprolol,Solute_carrier_organic_anion_transporter_family_member_1A2-Substrate,negative
359,CC(O)(CC(=O)O)CC(=O)O,Meglutol,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
360,CCC[C@H](N[C@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,Perindopril,GST-Inhibitor,negative
361,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Hydrocodone,2D6-Substrate,negative
362,C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O,ABT_761,2E1-Substrate,negative
363,COc1ccc2ccc(=O)oc2c1,7_methoxy_coumarin,2E1-Substrate,negative
364,CC[C@H](C)[C@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O,Vasopressin,Solute_carrier_family_12_member_1-Inducer,negative
365,CC(C)n1c(C=C[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,Fluvastatin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
366,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,Resiquimod,-,negative
367,CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,Dexloxiglumide,-,negative
368,CCC(=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,Methadone,CP2CI-Substrate,negative
369,CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,Bumetanide,Solute_carrier_family_12_member_2-Inhibitor,negative
370,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,iloperidone,2D6-Substrate,negative
371,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,Adriamycin,GST-Substrate,negative
372,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,Aripiprazole,P450_HFLA-Substrate,negative
373,CC(=O)C[C@H](c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O,Acenocoumarol,-,negative
374,COc1ccc(C(=O)Nc2ccccc2[C@H](C)CN2CCCCC2)cc1,Encainide,2D6-Substrate,negative
375,NC(=O)NN=Cc1ccc([N+](=O)[O-])o1,Nitrofural,2D6-Substrate,negative
376,O=C1OC(c2ccc(O)c(S(=O)(=O)O)c2)(c2ccc(O)c(S(=O)(=O)O)c2)c2c(Br)c(Br)c(Br)c(Br)c21,Sulfobromophthalein,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
377,NS(=O)(=O)Cc1noc2ccccc12,Zonisamide,-,negative
378,N[C@@H]1CONC1=O,Cycloserine,Proton_coupled_amino_acid_transporter_1-Substrate,negative
379,CN(C)C(=N)NC(=N)N,Metformin,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
380,Oc1ncnc2[nH]ncc12,Allopurinol,2E1-Inhibitor,negative
381,Oc1ccc(O)cc1,Hydroquinone,3A4-Substrate,negative
382,CC(=O)c1cc2ccccc2s1,2_acetylbenzothiophene,2E1-Substrate,negative
383,CC[C@]1(C)CC(=O)NC1=O,Ethosuximide,2E1-Substrate,negative
384,c1ccc2c(c1)ccc1ccccc12,phenanthrene,1A2-Substrate,negative
385,Cc1cc(N(C)C)ccc1CC(C)N,Amiflamine,2D6-Substrate,negative
386,O=[N+]([O-])c1ccc(O)cc1,4_nitrophenol,2E1-Substrate,negative
387,Cc1c(-c2cnccn2)ssc1=S,Oltipraz,-,negative
388,C[C@H](N)[C@H](O)c1cccc(O)c1,Metaraminol,Sodium_dependent_noradrenaline_transporter-Substrate,negative
389,CN[C@@]1(c2ccccc2Cl)CCCCC1=O,Ketamine,2D6-Substrate,negative
390,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](CC)C[C@@]21C,org_4060,3A4-Substrate,negative
391,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,Zaleplon,P450_HFLA-Substrate,negative
392,O=C1C(=C2Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21,Indigo Carmine,Coumarin_7_hydroxylase-Inhibitor,negative
393,CCO,Ethanol,1A1-Inhibitor,positive
394,Cc1ncc2c(c1O)CO[C@@H]2c1ccc(Cl)cc1,Cicletanine,UGT-Substrate,negative
395,CN[C@H](C)Cc1ccc2c(c1)OCO2,MDMA_R,2D6-Substrate,negative
396,O=C1CN=C(c2ccccc2F)c2cc(Cl)ccc2N1CC(F)(F)F,2_oxo_quazepam,2C9-Substrate,negative
397,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1,Niflumic Acid,Monocarboxylate_transporter_1-Inhibitor,negative
398,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1,Brompheniramine,2E1-Substrate,negative
399,CCNc1nc(NC(C)C)nc(SC)n1,ametryne,2C19-Substrate,negative
400,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1c1cccc(Cl)c1Cl,Felodipine,P450_HFLA-Substrate,negative
401,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,buprenorphine,2C8-Substrate,negative
402,CCOC(=O)C[C@H](SP(=S)(OC)OC)C(=O)OCC,Malathion,-,negative
403,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,Pranidipine,-,negative
404,NCCS,Mercaptamine,GST-Inhibitor,negative
405,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,Retigabine,1A1-Substrate,negative
406,COc1ccc2[n-]c(S(=O)Cc3ncc(C)c(OC)c3C)nc2c1,Esomeprazole,2C19-Substrate,negative
407,NC(=O)N1C(=O)C(=C(O)c2cccs2)c2cc(Cl)ccc21,Tenidap,Electrogenic_sodium_bicarbonate_cotransporter_1-Inhibitor,negative
408,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)C=CC=CC[C@@H](C)OC(=O)C[C@H]1OC(C)=O,Josamycin,-,negative
409,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,Lindane,N_acetyltransferase-Inducer,negative
410,Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12,ellipticine,2D6-Substrate,negative
411,C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@H](C(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H]([C@H](C)O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]([C@H](C)O)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCCCN)NC1=O,Somatostatin,2D6-Inhibitor,negative
412,c1ccc(-c2ccc([C@H](c3ccccc3)n3ccnc3)cc2)cc1,Bifonazole,19A-Inhibitor,negative
413,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,Amoxapine,2D6-Substrate,negative
414,C[C@H](COc1ccccc1)N(CCCl)Cc1ccccc1,Phenoxybenzamine,3A4-Substrate,negative
415,CC(C)(C)NC(=O)[C@@H]1C[C@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,Saquinavir,P450_HFLA-Substrate,negative
416,Cc1cnc2ccc3c(nc(N)n3C)c2n1,2_amino_3_8_dimethylimidazo_4_5_f_quinoxaline,1A2-Substrate,negative
417,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,Vernakalant,2D6-Substrate,negative
418,CC[C@@H]1C(C)=NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc21,Tofisopam,3A4-Inhibitor,negative
419,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Testosterone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
420,CCC(C)(C)OC,tert_amyl_methyl_ether,2E1-Substrate,negative
421,O=C(Nc1ccc2c(=O)cc(-c3nnn[nH]3)oc2c1)c1ccc(OCCCCc2ccccc2)cc1,Pranlukast,Solute_carrier_family_22_member_11-Inhibitor,negative
422,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,Pilocarpine,2E1-Substrate,negative
423,O=C(c1cccs1)c1ccc(OCc2nnn[nH]2)c(Cl)c1Cl,tienilic_acid_newderiv_9,2C9-Substrate,negative
424,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,Melphalan,GST-Substrate,negative
425,CC12CCC3C(CCC4=CC(=O)C=CC43C)C1CCC(=O)O2,Testolactone,-,negative
426,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,Metandienone,3A4-Substrate,negative
427,CN1C2CCC1CC(NC(=O)c1cc(Cl)cc3c1OC(C)(C)C3)C2,Zatosetron,-,negative
428,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Azithromycin,-,negative
429,CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)OCc1cccc(Oc2ccccc2)c1,Permethrin,2B6-Inducer,negative
430,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,Epirubicin,Multidrug_resistance_associated_protein_1-Inducer,negative
431,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,Nevirapine,2D6-Substrate,negative
432,COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1,Mebendazole,-,negative
433,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@H]3CC[C@@H](C(=O)N(C)C)N3)[C@H](C)[C@H]12,Meropenem,Solute_carrier_family_22_member_6-Substrate,negative
434,COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O,Diosmectite,1A1-Inhibitor,positive
435,CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12,Pindolol,2D6-Substrate,negative
436,CC[S@@](=O)c1c(C#N)nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c1N,ethiprole,3A4-Substrate,negative
437,CN(C)CCO[C@@](C)(c1ccccc1)c1ccccn1,Doxylamin,P450_HFLA-Inducer,negative
438,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,taxol,2C8-Substrate,negative
439,COc1ccc2c3c1OC1C(O)C=CC4C(C2)NCCC341,Norcodeine,2D6-Substrate,negative
440,CC1=CC(=O)[C@@H]2C[C@H]1C2(C)C,Levoverbenone,2B6-Substrate,negative
441,O=C(O)CCC/C=C\C[C@@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,S_145,2C9-Substrate,negative
442,Clc1ccc(CON=C(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,Oxiconazole,-,negative
443,C[N+](C)([O-])CCCN1c2ccccc2CCc2ccccc21,Imipramine Oxide,1A2-Substrate,negative
444,O=C1CC(=O)N(c2ccccc2)c2cc(Cl)ccc2N1,N_desmethyl_clobazapam,2C19-Substrate,negative
445,COc1ccc(C(=O)N2CCN(c3ccc4c(c3)CCC(=O)N4)CC2)cc1OC,Vesnarinone,-,negative
446,CCN(CC)C(=O)SC,DETC_Me,2E1-Substrate,negative
447,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1c1cccc([N+](=O)[O-])c1,Nitrendipine,P450_HFLA-Substrate,negative
448,CCOc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_ethoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
449,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,Telmisartan,-,negative
450,C=CC[C@]1(O)CC[C@H]2[C@H]3CCC4=CCCC[C@H]4[C@@H]3CC[C@]21C,Allylestrenol,3A4-Substrate,negative
451,OC[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](O[C@@H]4[C@@H](O)[C@H](O[C@@H]5[C@@H](O)[C@H](O)O[C@H](CO[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@H]5O)O[C@H](CO)[C@H]4O)O[C@H](CO)[C@H]3O)O[C@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Lentinan,1A1-Inhibitor,positive
452,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,Lornoxicam,-,negative
453,CCCCN(C)N=O,NN_methyl_butyl_nitrosoamine,2E1-Substrate,negative
454,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,Bromocriptine,-,negative
455,O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1,Bromazepam,2E1-Inhibitor,negative
456,Nc1nc(=O)c(Br)c(-c2ccccc2)[nH]1,bropirimine,1A2-Substrate,negative
457,CCOCn1c(Cc2ccccc2)c(C(C)C)c(=O)[nH]c1=O,Emivirine,-,negative
458,CCC(c1ccc(O)c(F)c1)C(C)c1ccc(O)c(F)c1,Bifluranol,-,negative
459,C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,Tiotropium Bromide,2D6-Substrate,negative
460,CCOP(=S)(OCC)SCSCC,phorate,2C19-Substrate,negative
461,CNNCc1ccc(C(=O)NC(C)C)cc1,Procarbazine,1B1-Substrate,negative
462,CCCCCCCCCCCCCCCC(=O)O,palmitic_acid,2E1-Substrate,negative
463,O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,Linopirdine,P450_HFLA-Substrate,negative
464,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,Pravastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
465,CN1CCCC1c1cccnc1,nicotine,2D6-Substrate,negative
466,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,Lumiracoxib,Solute_carrier_family_22_member_6-Inhibitor,negative
467,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digitoxin,SUL-Substrate,negative
468,COc1ccc(OC(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1,cp_122_721,2D6-Substrate,negative
469,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,Olanzapine,GST-Inducer,negative
470,CC/C=C\Cn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_11,3A4-Substrate,negative
471,CC(NCC(O)COc1cccc2ccccc12)C(F)F,difluoro_propranolol,2D6-Substrate,negative
472,O=[N+]([O-])OC1COC2C(O[N+](=O)[O-])COC12,Isosorbide dinitrate,-,negative
473,CN/C(=C\[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,ranitidine,2D6-Substrate,negative
474,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,Phenoxymethylpenicillin,3A4-Inducer,negative
475,CCN(C)N=O,NN_methyl_ethyl_nitrosoamine,2E1-Substrate,negative
476,CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,phenprocoumon_S,2C19-Substrate,negative
477,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,Molindone,2D6-Substrate,negative
478,COc1cc(Br)c2oc(C3CCNCC3)cc2c1,Brofaromine,2D6-Substrate,negative
479,COc1ccc([N+](=O)[O-])cc1,4_nitroanisole,2E1-Substrate,negative
480,CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1,Propafenone,2D6-Inhibitor,negative
481,Oc1ccc(C(c2ccc(O)cc2)C(Cl)(Cl)Cl)cc1,bis_OH_methoxychlor,3A4-Substrate,negative
482,CCc1ccccc1,Ethylbenzene,-,negative
483,COc1ccc2[nH]c(S(=O)Cc3ncc(C)c(OC)c3C)nc2c1,Omeprazole,1A1-Inhibitor,positive
484,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,Dextropropoxyphene,P450_HFLA-Inducer,negative
485,COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,Pantoprazole,SUL-Substrate,negative
486,C(=C/c1ccccc1)\c1ccccc1,trans_stilbene,2D6-Substrate,negative
487,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,Fluticasone,-,negative
488,C1CCC(C(C[C@H]2CCCCN2)C2CCCCC2)CC1,Perhexiline,2D6-Substrate,negative
489,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,Simvastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
490,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin_Mb2,3A4-Substrate,negative
491,COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1,tangeretin,2D6-Substrate,negative
492,CCCN(CCC)N=O,NN_dipropyl_nitrosoamine,2E1-Substrate,negative
493,Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1,Bupranolol,2D6-Substrate,negative
494,CN(C)c1ccc(C2CC3(C)C(CCC3(O)C=CCO)C3CCC4=CC(=O)CCC4=C23)cc1,Lilopristone,-,negative
495,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,Ibutilide,-,negative
496,CN1CCN2c3ncccc3Cc3ccccc3[C@@H]2C1,mirtazapine_R,2D6-Substrate,negative
497,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,Nefazodone,P450_HFLA-Inhibitor,negative
498,CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,NE_100,2D6-Substrate,negative
499,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,13_cis_retinoic_acid,2E1-Substrate,negative
500,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,Midazolam,P450_HFLA-Inhibitor,negative
501,O=NN1CCC[C@H]1c1cccnc1,N_nitroso_nornicotine,3A4-Substrate,negative
502,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,Deferoxamine,1A1-Inhibitor,positive
503,CCC[N@@+]12[C@H]3C[C@@]45c6ccccc6N(C)[C@H]4[C@@H]1C[C@H]([C@@H]3[C@H]5O)[C@H](CC)[C@H]2O,Prajmaline,2D6-Substrate,negative
504,CC(O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,Lisofylline,-,negative
505,[Cl-].[K+],Potassium Chloride,Solute_carrier_family_12_member_2-Substrate,negative
506,O=NN(CCCl)C(=O)NCCCl,Carmustine,GST-Substrate,negative
507,CN(C)CCN(Cc1ccccc1)c1ccccn1,Tripelennamine,2D6-Inhibitor,negative
508,O=S(=O)([O-])[S-],Thiosulfate,2E1-Inhibitor,negative
509,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,Mitomycin,1A2-Inducer,negative
510,c1cnc2cc3c(cc2n1)[C@H]1CNC[C@@H]3C1,Varenicline,Methyltransferase-Inhibitor,negative
511,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1,Mirtazapine,2D6-Inhibitor,negative
512,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Sirolimus,P450_HFLA-Substrate,negative
513,C1=CCCCC1,cyclohexene,2E1-Substrate,negative
514,CS(=O)(=O)OCCCCOS(C)(=O)=O,Busulfan,GST-Substrate,negative
515,CCN[C@@H]1C[C@@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,Dorzolamide,2E1-Substrate,negative
516,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO,Desoxycortone,Steroid_11_beta_hydroxylase-Substrate,negative
517,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,Dipyridamole,Multidrug_resistance_associated_protein_1-Inhibitor,negative
518,O=C(NC[C@@H]1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F,Flecainide,2D6-Substrate,negative
519,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-],Sodium Edetate,3A4-Substrate,negative
520,[Ag],Silver,Probable_low_affinity_copper_uptake_protein_2-Inhibitor,negative
521,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,Irinotecan,P450_HFLA-Substrate,negative
522,CCN(CC)C(=O)c1cccc(C)c1,Diethyltoluamide,2E1-Substrate,negative
523,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,Desvenlafaxine,2D6-Substrate,negative
524,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,Troleandomycin,CP2CI-Inhibitor,negative
525,Cc1cccc(C)c1NC(=O)[C@H](C)N,Tocainide,1A1-Inhibitor,positive
526,Cn1c(N)nc2c3cccnc3ccc21,2_amino_3_methylimidazo_4_5_f_quinoline,1A2-Substrate,negative
527,S=c1[nH]cnc2nc[nH]c12,Mercaptopurine,Solute_carrier_family_28_member_3-Substrate,negative
528,CC(Nc1cc(-c2[nH]c(S(C)=O)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,ML_3603,2D6-Substrate,negative
529,COc1ccc(NC(C)=O)cc1,O_methyl_acetaminophen,1A2-Substrate,negative
530,Cc1nc[nH]c1CN1CCc2c(c3ccccc3n2C)C1=O,Alosetron,2E1-Inhibitor,negative
531,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)C1=O,9_alpha_fluoro_androstadienedione,3A4-Substrate,negative
532,O=C1C[C@H](c2ccc(O)cc2)Oc2cc(O)cc(O)c21,naringenin,1A2-Substrate,negative
533,COCCCCC(=NOCCN)c1ccc(C(F)(F)F)cc1,Fluvoxamine,1A1-Inhibitor,positive
534,COCCc1ccc(OC[C@H](O)CNC(C)C)cc1,Metoprolol,2D6-Substrate,negative
535,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,Voriconazole,-,negative
536,C[C@@]12CC[C@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@@H]3[C@@H]1CC[C@@H]2O,Estramustine,3A4-Substrate,negative
537,N#N,Nitrogen,Solute_carrier_family_15_member_1-Substrate,negative
538,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,Ergotamine,-,negative
539,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc2nonc12,Isradipine,-,negative
540,O=C1[C@@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,Ezetimibe,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
541,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,Benidipine,1A1-Inhibitor,positive
542,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O,Amobarbital,Coumarin_7_hydroxylase-Inducer,negative
543,CC12C=CC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,Boldenone,-,negative
544,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Cortisone,SUL-Inhibitor,negative
545,[Cl-].[Na+],Sodium Chloride,2E1-Inducer,negative
546,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,retinol,2D6-Substrate,negative
547,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,Nilutamide,-,negative
548,OC(c1ccccc1)(c1ccccc1)C1CCNCC1,Azacyclonol,-,negative
549,O=c1[nH]cc(F)c(=O)[nH]1,Fluorouracil,-,negative
550,O=c1c(O)c(-c2ccccc2)oc2cc(O)cc(O)c12,galangin,2C9-Substrate,negative
551,CC(=O)O,Acetic Acid,2E1-Substrate,negative
552,O=c1cc(C(F)(F)F)c2ccc(OCc3ccccc3)cc2o1,7_benzyloxy_4_trifluoromethyl_coumarin,2C19-Substrate,negative
553,CCN(CC)CC#CCOC(=O)[C@@](O)(c1ccccc1)C1CCCCC1,Oxybutynin,2D6-Inhibitor,negative
554,O=C1c2ccccc2C(=O)c2ccccc21,Anthraquinone,-,negative
555,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,Clonazepam,-,negative
556,CCC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Hydroquinidine,-,negative
557,CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,warfarin_S,2C19-Substrate,negative
558,CN1CCN2c3ccccc3Cc3ccccc3[C@@H]2C1,mianserin_R,2D6-Substrate,negative
559,C=Cc1ccccc1,styrene,2E1-Substrate,negative
560,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,Risperidone,P450_HFLA-Substrate,negative
561,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,Fluconazole,CP2CI-Inhibitor,negative
562,CC(C=CC1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(=O)O,Alitretinoin,1A2-Inhibitor,negative
563,C[C@@H]1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1,Temafloxacin,1A2-Substrate,negative
564,CCC1(CC)C(=O)NC[C@@H](C)C1=O,Methyprylon,2D6-Substrate,negative
565,C[C@@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Clobetasol,1A1-Inhibitor,positive
566,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Ketoconazole,1A1-Inhibitor,positive
567,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,Fluphenazine,2E1-Inhibitor,negative
568,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,Tazarotene,2C8-Substrate,negative
569,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfamerazine,-,negative
570,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,Lansoprazole,4A11-Inducer,negative
571,CC(C=CC=C(C)C=CC1=C(C)CCCC1(C)C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C,Betacarotene,GST-Inducer,negative
572,CCCCNCc1cc(=O)oc2cc(OC)ccc12,BMAMC,2D6-Substrate,negative
573,CC(Cc1ccccc1)N(C)Cc1ccccc1,Benzfetamine,-,negative
574,O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1,Fenbufen,Multidrug_resistance_protein_1-Inducer,negative
575,C[C@@H](C(=O)O)c1ccc(C(=O)c2ccccc2)s1,Tiaprofenic Acid,GST-Inhibitor,negative
576,OCCSCCCCCCCCCCSCCO,Tiadenol,UGT-Inducer,negative
577,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,9_cis_retinoic_acid,2C9-Substrate,negative
578,CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C,Glycyrrhizic Acid,P450_HFLA-Inducer,negative
579,C=CC1(C)CO1,isoprene_epoxide_1,2E1-Substrate,negative
580,CC(C)(C)NCC(O)COc1ccccc1C#N,Bunitrolol,2D6-Substrate,negative
581,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,Codeine,P450_HFLA-Substrate,negative
582,CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,Dronabinol,-,negative
583,Cc1ccccc1[C@H](OCCN(C)C)c1ccccc1,Orphenadrine (citrate),2D6-Inhibitor,negative
584,O=[N+]([O-])O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@H]12,Isosorbide Mononitrate,3A4-Substrate,negative
585,O[C@@](CCN1CCCCC1)(c1ccccc1)[C@@H]1C[C@@H]2C=C[C@H]1C2,Biperiden,2D6-Inhibitor,negative
586,COc1ccc(C(c2ccc(O)cc2)C(Cl)(Cl)Cl)cc1,mono_OH_methoxychlor,2E1-Substrate,negative
587,C[C@H](C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,Pirprofen,UGT-Substrate,negative
588,Nc1nc(OCc2ccccc2)c2nc[nH]c2n1,O6_benzylguanine,1A2-Substrate,negative
589,CCNCc1cc(=O)oc2cc(OC)ccc12,EMAMC,2D6-Substrate,negative
590,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Flurithromycin,-,negative
591,CC(CO)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,ipriflavone_M4,1A2-Substrate,negative
592,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,Oxycodone,19A-Inhibitor,negative
593,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,-,negative
594,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,Formoterol,2D6-Substrate,negative
595,O=C(O)CC[C@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,tetranor,2C9-Substrate,negative
596,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O,Nandrolone,19A-Substrate,negative
597,CC(C)O,Isopropanol,2E1-Inducer,negative
598,CCCCCCCCC,nonane,2E1-Substrate,negative
599,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1C=CC(=O)OC(C)(C)C,Lacidipine,-,negative
600,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,Nimesulide,2C9-Inhibitor,negative
601,C=CC[C@@H]1C=C(C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](C(C)=C[C@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,Tacrolimus,P450_HFLA-Substrate,negative
602,CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,Streptozocin,2E1-Inducer,negative
603,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,perhexiline,2D6-Substrate,negative
604,CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21,Medazepam,2E1-Inhibitor,negative
605,CC(C)(C)C1CCC(C2=C(O)c3ccccc3C(=O)C2=O)CC1,58C80_tautomer_1,2C9-Substrate,negative
606,c1ccc2ncccc2c1,quinoline,2E1-Substrate,negative
607,CC(C)(CO)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_OH_finasteride,3A4-Substrate,negative
608,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,Ciprofloxacin,2E1-Inducer,negative
609,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,Tryptophan,1B1-Inducer,negative
610,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,Chlordiazepoxide,2D6-Substrate,negative
611,Cc1c(C)c2c(c(C)c1O)CC[C@](C)(COc1ccc(C[C@H]3SC(=O)NC3=O)cc1)O2,troglitazone,2C8-Substrate,negative
612,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,Ranolazine,-,negative
613,c1ccc2c(c1)ccc1nc3ccc4ccccc4c3cc12,dibenzacridine,1A2-Substrate,negative
614,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21,Enoxacin,-,negative
615,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,Buflomedil,2D6-Substrate,negative
616,CCOC(C)(C)C,ethyl_tert_butyl_ether,2E1-Substrate,negative
617,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,Fingolimod,4F2-Substrate,negative
618,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12,Aldosterone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer,negative
619,CCC1(c2ccncc2)CCC(=O)NC1=O,Rogletimide,-,negative
620,CC(NCC(O)COc1cccc2ccccc12)C(C)(C)C,tert_butyl_propranolol,2D6-Substrate,negative
621,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Cetirizine,-,negative
622,CC(C)NNC(=O)c1ccncc1,Iproniazide,N_acetyltransferase-Inhibitor,negative
623,C[C@H](C(=O)O)c1ccc(C(=O)c2cccs2)cc1,Suprofen,-,negative
624,C=C[C@@H](N)CCC(=O)O,Vigabatrin,Proton_coupled_amino_acid_transporter_1-Substrate,negative
625,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2,Ivabradine,3A4-Substrate,negative
626,O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,Phenolphthalein,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
627,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,Clomifene,19A-Inhibitor,negative
628,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,Prochlorperazine,2D6-Substrate,negative
629,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,Domperidone,P450_HFLA-Substrate,negative
630,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(C=Cc2ccc3ccc(Cl)cc3n2)c1,Montelukast,-,negative
631,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfadimidine,-,negative
632,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C,Lynestrenol,2C19-Inducer,negative
633,NC[C@H](O)c1ccc(O)cc1,Octopamine,2D6-Substrate,negative
634,COc1ccc2c(c1)Oc1cc(O)ccc1C21OC(=O)c2ccccc21,3_O_methyl_fluorescein,2C19-Substrate,negative
635,CN1C(=O)C[C@@](C)(c2ccccc2)C1=O,Mesuximide,2C19-Inhibitor,negative
636,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,Letrozole,19A-Inhibitor,negative
637,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,Zidovudine,-,negative
638,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,Toremifene,-,negative
639,CCCCN(CCCC)N=O,NN_dibutyl_nitrosoamine,2E1-Substrate,negative
640,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Aceclofenac,-,negative
641,CC(=O)[C@@]1(C)CC[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]21C,Medrogestone,3A4-Substrate,negative
642,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,Decitabine,Methyltransferase-Inhibitor,negative
643,CCN(CC)CC(=O)Nc1c(C)cccc1C,Lidocain,CP2CI-Substrate,negative
644,CS(C)=O,Dimethyl Sulfoxide,2D6-Inhibitor,negative
645,O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,Efavirenz,2D6-Inhibitor,negative
646,CC[N+](C)(CC)CCc1c(C(F)(F)F)c2ccc(OC)cc2oc1=O,MeAMFC,2D6-Substrate,negative
647,COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2,aflatoxin_B1,1A2-Substrate,negative
648,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,Cyproheptadin,UGT-Substrate,negative
649,Nc1ccc(C(=O)O)cc1,Aminobenzoic Acid,SUL-Substrate,negative
650,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,Albendazole,2D6-Substrate,negative
651,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,Azacitidine,Methyltransferase-Inhibitor,negative
652,CN[C@]1(c2ccccc2Cl)CCCCC1=O,Esketamine,2B6-Substrate,negative
653,CN(C)C(=S)SSC(=S)N(C)C,Thiram,2E1-Substrate,negative
654,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cyclizine,2C9-Inhibitor,negative
655,NCCCC(=O)O,Aminobutyric Acid,2D6-Substrate,negative
656,COc1cc2c(CCN3CCN(c4cccc(Cl)c4C)CC3)nn(Cc3c[nH]cn3)c2cc1OC,DY_9760e,2D6-Substrate,negative
657,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@@]21C,lithocholic_acid,3A4-Substrate,negative
658,CCC(N)Cc1ccc2c(c1)OCO2,BDB,2D6-Substrate,negative
659,Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1,Sulfadiazine,2E1-Substrate,negative
660,COC(F)(F)C(Cl)Cl,Methoxyflurane,2E1-Substrate,negative
661,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,Candesartan,-,negative
662,C=CC1CC=CCC1,4_vinylcyclohexene,2E1-Substrate,negative
663,C=C1CC[C@@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,Calcifediol,24A-Substrate,negative
664,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Erythromycin,P450_HFLA-Substrate,negative
665,Cc1ccc(=O)n(-c2ccccc2)c1,Pirfenidone,1A2-Substrate,negative
666,C[C@H](N)Cc1ccccc1,Dexamfetamine,2D6-Inhibitor,negative
667,COc1ccc2c(c1OC)C(=O)O[C@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,Noscapine,2C19-Inhibitor,negative
668,O=[P@]1(N(CCCl)CCCl)OCCCN1CCCl,trofosfamide,3A4-Substrate,negative
669,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,Almotriptan,2D6-Substrate,negative
670,COc1ccc(-c2cc(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]5O)[C@H](O)[C@H](O)[C@H]4O)cc3o2)cc1O,Diosmin,1A1-Inhibitor,positive
671,NC(=O)CC[C@H](N)C(=O)O,Levoglutamide,Neutral_amino_acid_transporter_B0-Substrate,negative
672,CC(C)(C)NC[C@H](O)c1cc(Cl)c(N)c(Cl)c1,Clenbuterol,1A2-Substrate,negative
673,CC(C)N(CC[C@](C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,Disopyramide,-,negative
674,Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,Pemetrexed,Proton_coupled_folate_transporter-Substrate,negative
675,Nc1nc2[nH]cnc2c(=S)[nH]1,Tioguanine,Solute_carrier_family_28_member_3-Substrate,negative
676,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Hydrocortisone,GST-Inducer,negative
677,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1C2=Cc1ccc(Cl)cc1,Lumefantrine,-,negative
678,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,Tenoxicam,-,negative
679,Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,Sulfapyridine,-,negative
680,CCOc1ccc2c(Cl)cc(=O)oc2c1,4_chloro_7_ethoxycoumarin,2C19-Substrate,negative
681,C[C@@H](CN1c2ccccc2Sc2ccc(S(=O)(=O)N(C)C)cc21)N(C)C,Dimetotiazine,3A4-Inhibitor,negative
682,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,Lovastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
683,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nn[nH]n3)c2)nc1OCCO,Tezosentan,-,negative
684,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O,Benzylpenicillin,Canalicular_multispecific_organic_anion_transporter_1-Inducer,negative
685,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,Teniposide,-,negative
686,[Li],Lithium,Solute_carrier_family_12_member_2-Inducer,negative
687,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Atazanavir,1A1-Inhibitor,positive
688,CC(=O)NCC1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,Linezolid,-,negative
689,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O,Phenobarbital,4A11-Inducer,negative
690,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O,Griseofulvin,-,negative
691,COC1=CC(=O)OC1C(O)c1ccccc1Cl,Losigamone,-,negative
692,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21,Norfloxacin,1A1-Inhibitor,positive
693,O=C(c1cccs1)c1ccc(O)c(Cl)c1Cl,tienilic_acid_deriv_1,2C9-Substrate,negative
694,CNCCC=C1c2ccccc2CCc2ccccc21,Nortriptyline,2E1-Inhibitor,negative
695,CCOP(=S)(OCC)SCCSCC,disulfoton,2D6-Substrate,negative
696,Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,FLU,2C9-Substrate,negative
697,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1,Liarozole,-,negative
698,COc1ccc2cc(C#N)c(=O)oc2c1,7_methoxy_3_cyano_coumarin,2E1-Substrate,negative
699,CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl,Clotiazepam,CP2CI-Substrate,negative
700,O=[As]1=[As](=O)O1,Arsenic Trioxide,1A1-Inhibitor,positive
701,CCC(C(=O)c1ccc(C)cc1)N1CCCC1,MPBP,2D6-Substrate,negative
702,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2,Camphora,GST-Inducer,negative
703,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)C=C[C@H](C)C(C)C,Ergocalciferol,Arachidonic_acid_epoxygenase-Substrate,negative
704,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,Paroxetine,2D6-Inhibitor,negative
705,NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,Famotidine,-,negative
706,COC1=C[C@@H](C)[C@@H]2C[C@@H]3OC(=O)C[C@H]4C(C)=C(OC)C(=O)[C@H]([C@@]2(C)C1=O)[C@]34C,Quassia,1A1-Inhibitor,positive
707,CCNC(=O)[C@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H]1CCC(=O)N1,Buserelin,19A-Inducer,negative
708,NCCc1c[nH]cn1,Histamine,2E1-Inducer,negative
709,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,sibutramine,2C19-Substrate,negative
710,NCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Norfluoxetine,2D6-Substrate,negative
711,CCCc1cc(=O)[nH]c(=S)[nH]1,Propylthiouracil,GST-Inhibitor,negative
712,CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1,Remacemide,-,negative
713,C[C@@H](N)Cc1ccccc1,Amfetamine,2D6-Inhibitor,negative
714,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,Tamoxifen,19A-Inhibitor,negative
715,C[C@@H]1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23,Flumequine,2E1-Inhibitor,negative
716,Cn1nnc2ccc([C@H](c3ccc(Cl)cc3)n3cncn3)cc21,Vorozole,19A-Inhibitor,negative
717,Cc1ccccc1-n1c(C)nc2ccccc2c1=O,Methaqualone,-,negative
718,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,Cisapride,GST-Inducer,negative
719,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,Loperamide,2D6-Substrate,negative
720,CC(C)[C@]12CC(=O)[C@H](C)[C@H]1C2,alpha_thujone,3A4-Substrate,negative
721,Fc1cccc2c1OC1CNCC1O2,Fluparoxan,-,negative
722,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,Atorvastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
723,CCN[C@@H]1C[C@H](N)[C@@H](O[C@@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O,Netilmicin,N_acetyltransferase-Substrate,negative
724,CN(C)CCCN1c2ccccc2CCc2ccccc21,Imipramine,CP2CI-Substrate,negative
725,CCCCCCCCCCCCCCCCCC(=O)O,stearic_acid,2E1-Substrate,negative
726,Nc1ccc(C(=O)O)c(O)c1,Aminosalicylic Acid,Sodium_coupled_neutral_amino_acid_transporter_3-Substrate,negative
727,CN(C)S(=O)(=O)CCNC(=O)N(CCCl)N=O,tauromustine,2D6-Substrate,negative
728,CCN(CC)CCNC(=O)c1ccc(N)cc1,Procainamide,2D6-Substrate,negative
729,O=c1[nH]c2cc(Cl)ccc2o1,chlorzoxazone,2E1-Substrate,negative
730,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,Atomoxetine,2D6-Inhibitor,negative
731,Fc1cccc(CCN2CCN(CCCc3c[nH]c4ccc(-n5cnnc5)cc34)CC2)c1,L_775_606,2C8-Substrate,negative
732,C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Quinine,-,negative
733,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,Captopril,Methyltransferase-Substrate,negative
734,O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1,Flufenamic Acid,2E1-Inducer,negative
735,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3OC5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,etoposide,2E1-Substrate,negative
736,C#CC1(O)C=CC2C3CCC4=CC(=O)CCC4C3CCC21CC,Gestodene,-,negative
737,CCCCOC(=O)c1ccccc1C(=O)OCCCC,Dibutylphthalate,19A-Inducer,negative
738,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@](C)(OC)[C@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,Roxithromycin,-,negative
739,CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1,Lofepramine,2D6-Substrate,negative
740,CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,Tiotixene,2D6-Inhibitor,negative
741,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C[C@H]2C=Nc3ccccc32)NC[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN3CCN(CC(=O)O)CC(=O)O[In](OC(=O)C3)OC(=O)C2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,Indium (111In) Pentetic Acid,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
742,COc1cc2nc(N(C)CCCNC(=O)[C@H]3CCCO3)nc(N)c2cc1OC,Alfuzosin,3A4-Substrate,negative
743,Cc1nccn1C[C@H]1CCc2c(c3ccccc3n2C)C1=O,Ondansetron,2E1-Substrate,negative
744,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Adenosine,Sodiumbile_acid_cotransporter-Inducer,negative
745,C[C@H](CN(C)C)CN1c2ccccc2S(=O)(=O)c2ccccc21,Oxomemazine,-,negative
746,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisolone,-,negative
747,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,Gemfibrozil,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
748,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,Sertraline,2D6-Inhibitor,negative
749,CCN(CC)CCS(=O)(=O)C1CCN2C(=O)c3coc(n3)CC(=O)CC(O)C=C(C)C=CCNC(=O)C=CC(C)C(C(C)C)OC(=O)C12,Dalfopristin,-,negative
750,S=P(N1CC1)(N1CC1)N1CC1,Thiotepa,GST-Substrate,negative
751,CCCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_5,3A4-Substrate,negative
752,CCC1CC2CC3c4[nH]c5ccc(OC)cc5c4CCN(C2)C13,12_methoxy_ibogamine,2D6-Substrate,negative
753,O=C(O)c1cc(N=Nc2ccc(O)c(C(=O)O)c2)ccc1O,Olsalazine,Methyltransferase-Inhibitor,negative
754,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@]21CCC(=O)O1,Canrenone,UGT-Inhibitor,negative
755,CCCCN(CCCC)CC[C@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,Halofantrine,2D6-Inhibitor,negative
756,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,Hydrochlorothiazide,Solute_carrier_family_12_member_1-Inducer,negative
757,CCCCCCCC(C)O,2_nonanol,2E1-Substrate,negative
758,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Doxycycline,-,negative
759,C=CC1CO1,butadienemonoxide,2E1-Substrate,negative
760,C[C@@H](O)C(=O)O,Milchsäure,Monocarboxylate_transporter_1-Substrate,negative
761,ClC1=C(Cl)C2(Cl)C3C4CC(C5OC45)C3C1(Cl)C2(Cl)Cl,Dieldrin,-,negative
762,O=C(O)CCCC[C@@H]1SC[C@H]2NC(=O)N[C@H]21,Biotin,1B1-Inducer,negative
763,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,Pitavastatin,UGT-Inhibitor,negative
764,CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1,Delavirdine,2D6-Inhibitor,negative
765,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,Flutamide,-,negative
766,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@@H]4[C@H](CC[C@]3(O)C2)[C@@]2(O)CC[C@H](C3=CC(=O)OC3)[C@@]2(C)C[C@H]4O)[C@H](O)[C@H](O)[C@H]1O,G-strophanthin,1A1-Inhibitor,positive
767,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,Ketoprofen,GST-Inhibitor,negative
768,CC(C)=O,Acetone,-,negative
769,Oc1ccccc1-c1ccccc1,O_phenylphenol,2E1-Substrate,negative
770,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Substrate,negative
771,CN(C)C(=O)Nc1ccc(Cl)c(Cl)c1,diuron,2E1-Substrate,negative
772,CC(C)C[C@@H](N(C)C)C1(c2ccc(Cl)cc2)CCC1,Sibutramine,-,negative
773,CC[C@H](OC(C)=O)C(C[C@H](C)NC)(c1ccccc1)c1ccccc1,norLAAM,2D6-Substrate,negative
774,CN1C(=O)[C@H](O)N=C(c2ccccc2)c2cc(Cl)ccc21,Temazepam,-,negative
775,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN[C@H](C)C3)c(F)c21,Lomefloxacin,-,negative
776,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,cinnarizine,2D6-Substrate,negative
777,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,Diazepam,CP2CI-Substrate,negative
778,CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,Eszopiclone,2E1-Substrate,negative
779,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,Zolpidem,P450_HFLA-Substrate,negative
780,CCCCNC(C)Cc1ccccc1,N_butyl_amphetamine,2D6-Substrate,negative
781,CC(C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,Angiotensinamide,Methyltransferase-Inducer,negative
782,CC(C)C[C@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,Bortezomib,1A1-Inhibitor,positive
783,NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,Pipamperone,GST-Inducer,negative
784,CC(C)(C(=O)c1cccnc1)c1cccnc1,Metyrapone,2E1-Inhibitor,negative
785,CC(=O)Nc1ccc(OC(C)C)cc1,O_isopropyl_acetaminophen,1A2-Substrate,negative
786,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,vicriviroc,2C9-Substrate,negative
787,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,Levothyroxine Sodium,3A4-Substrate,negative
788,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,Glimepiride,-,negative
789,CC(=O)OCC[N+](C)(C)C,Acetylcholin,Methyltransferase-Inducer,negative
790,CN(C)N/N=C1\N=CN=C1C(N)=O,dacarbazine,2E1-Substrate,negative
791,CCCCCN(C)N=O,N_amyl_N_methyl_nitrosamine,2E1-Substrate,negative
792,COc1cc2c(c(OC)c1OC)-c1c(cc(OC)c(OC)c1OC)C[C@@H](C)[C@@H](C)C2,deoxy_schizandrin,3A4-Substrate,negative
793,NCC1(CC(=O)O)CCCCC1,Gabapentin,GST-Inducer,negative
794,CCCCC/C=C/C/C=C/CCCCCCCC(=O)O,linoleic_acid,2E1-Substrate,negative
795,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,Probenecid,-,negative
796,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,montelukast,2D6-Substrate,negative
797,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CCC2=O,Prasterone,1A1-Inhibitor,positive
798,O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,Rebamipide,-,negative
799,C[C@H](c1cc2ccccc2s1)N(O)C(N)=O,zileuton_R,2E1-Substrate,negative
800,Cc1c(C)c2c(c(C)c1O)CC[C@](C)(COc1ccc(C[C@@H]3SC(=O)NC3=O)cc1)O2,Troglitazone,19A-Inhibitor,negative
801,COc1ccc2c(c1)[nH]c1c(C)nccc12,harmine,2D6-Substrate,negative
802,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,Rutoside,2D6-Inhibitor,negative
803,CCN1C(=O)N[C@@H](c2ccccc2)C1=O,Ethotoin,-,negative
804,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,Pilsicainide,-,negative
805,Cc1ccccc1,toluene,2E1-Substrate,negative
806,O=C(O)Cc1cc(O)ccc1Nc1c(Cl)cccc1Cl,5_hydroxy_diclofenac,2C9-Substrate,negative
807,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Diclofenac,CP2CI-Substrate,negative
808,CCCCC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,Propiverine,3A4-Inhibitor,negative
809,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O,Dinoprostone,19A-Inducer,negative
810,Clc1ccc(C(c2ccc(Cl)cc2)C(Cl)(Cl)Cl)cc1,Clofenotane,19A-Inhibitor,negative
811,C#CCNC1CCc2ccccc21,Rasagiline,1A2-Substrate,negative
812,CCC[C@@](C)(COC(N)=O)COC(=O)NC(C)C,Carisoprodol,-,negative
813,CC(C)(C=O)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_aldehyde_finasteride,3A4-Substrate,negative
814,O=[N+]([O-])NC1=NCCN1Cc1ccc(Cl)nc1,imidacloprid,2E1-Substrate,negative
815,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1,Sulfamethizole,-,negative
816,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21,Emedastine,-,negative
817,N#C[Fe](C#N)(C#N)(C#N)(C#N)N=O,Nitroprusside,1A1-Inhibitor,positive
818,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Bupivacaine,2D6-Substrate,negative
819,CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Chloroquine,Multidrug_and_toxin_extrusion_protein_1-Inhibitor,negative
820,CSc1nc(-c2ccnc(NC(C)c3ccccc3)c2)c(-c2ccc(F)cc2)[nH]1,ML_3403,2D6-Substrate,negative
821,CC(C)(C)NCC(O)COc1ccccc1C1CCCC1,Penbutolol,2D6-Substrate,negative
822,C[C@@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,flurbiprofen_R,2C9-Substrate,negative
823,O=S1OCC2C(CO1)C1(Cl)C(Cl)=C(Cl)C2(Cl)C1(Cl)Cl,endosulfan,2C19-Substrate,negative
824,OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1,Opipramol,2D6-Substrate,negative
825,c1cnc(N2CCNCC2)nc1,1_PP,2D6-Substrate,negative
826,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1O,tamarixetin,2C9-Substrate,negative
827,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O,Glutathione,19A-Inducer,negative
828,CN(C)CCCN1c2ccccc2Sc2ccccc21,promazine,2E1-Substrate,negative
829,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,Abiraterone,-,negative
830,CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1,Carbinoxamine,2E1-Substrate,negative
831,Cc1nnc2n1-c1sc(Br)cc1C(c1ccccc1Cl)=NC2,Brotizolam,-,negative
832,O=NN(CCCl)C(=O)NC1CCCCC1,Lomustine,2D6-Substrate,negative
833,Cc1c2oc3c(C)ccc(C(=O)N[C@H]4C(=O)N[C@@H](C(C)C)C(=O)N5CCC[C@@H]5C(=O)N(C)CC(=O)N(C)[C@H](C(C)C)C(=O)O[C@H]4C)c3nc-2c(C(=O)N[C@H]2C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@@H]3C(=O)N(C)CC(=O)N(C)[C@H](C(C)C)C(=O)O[C@H]2C)c(N)c1=O,Dactinomycin,1A1-Inhibitor,positive
834,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,Haloperidol,P450_HFLA-Substrate,negative
835,COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc([N+](=O)[O-])c1,Nilvadipine,2E1-Substrate,negative
836,CCOc1ccc2ccccc2c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,Nafcillin,-,negative
837,CN1C(=O)C[C@H](c2ccccc2)C1=O,Phensuximide,-,negative
838,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1,kaempferide,2C9-Substrate,negative
839,O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1,Thalidomide,CP2CI-Substrate,negative
840,CN(C)Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,Adinazolam,-,negative
841,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C,Tubocurarine,Methyltransferase-Inhibitor,negative
842,Cn1cnc2c1c(=O)n(CC1CCCO1)c(=O)n2C,theobromine_deriv_9,3A4-Substrate,negative
843,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C,Ciclesonide,3A4-Substrate,negative
844,Cc1onc(NS(=O)(=O)c2ccc(N)cc2)c1C,Sulfatroxazole,-,negative
845,NC(=O)c1cccnc1,Nicotinamide,2E1-Inhibitor,negative
846,CNCCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,desmethyl_citalopram,2D6-Substrate,negative
847,FC(F)(F)[C@@H](Cl)Br,Halothane,2E1-Substrate,negative
848,CO[C@@]12CC[C@]3(C[C@H]1[C@](C)(O)C(C)(C)C)[C@@H]1Cc4ccc(O)c5c4[C@]3(CCN1CC1CC1)[C@@H]2O5,Buprenorphine,CP2CI-Substrate,negative
849,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1,Sparteine,2D6-Inhibitor,negative
850,COc1ccc([C@H](CN(C)C)C2(O)CCCCC2)cc1,venlafaxine_R,2D6-Substrate,negative
851,Cc1nccn1C[C@@H]1CCc2c(c3ccccc3n2C)C1=O,ondansetron,2D6-Substrate,negative
852,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,Ergoloid Mesylates,Solute_carrier_organic_anion_transporter_family_member_2B1-Inhibitor,negative
853,O=C(O)c1ccc(OCCn2ccnc2)cc1,Dazoxiben,-,negative
854,CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,Pyrimethamine,GST-Inhibitor,negative
855,COc1cc2nc(N3CCN(C(=O)[C@@H]4COc5ccccc5O4)CC3)nc(N)c2cc1OC,Doxazosin,2D6-Substrate,negative
856,COc1c2ccoc2cc2oc(=O)ccc12,Bergapten,N_acetyltransferase-Inhibitor,negative
857,CCCCCN(CCCCC)N=O,NN_diamyl_nitrosoamine,2E1-Substrate,negative
858,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,Alprazolam,P450_HFLA-Substrate,negative
859,C=C(C)c1ccc(OC)c(CN[C@H]2C3CCN(CC3)[C@H]2C(c2ccccc2)c2ccccc2)c1,ezlopitant_alkene_CJ_12_458,2D6-Substrate,negative
860,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,Docetaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
861,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Terconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
862,Clc1cccc(Cl)c1NC1=NCCN1,Clonidine,19A-Inducer,negative
863,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1,Tirilazad,-,negative
864,O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,Fluorescein,Solute_carrier_family_22_member_6-Substrate,negative
865,COCc1c(C(=O)OC(C)C)ncc2[nH]c3ccc(OCc4ccccc4)cc3c12,Abecarnil,-,negative
866,O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,Mitiglinide,UGT-Substrate,negative
867,CCC(=C(CC)c1ccc(O)cc1)c1ccc(O)cc1,Diethylstilbestrol,19A-Inducer,negative
868,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21,Yohimbin,2D6-Inhibitor,negative
869,C[N+](C)(C)CCOC(N)=O,Carbachol,N_acetyltransferase-Inhibitor,negative
870,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digoxin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
871,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,Tolcapone,Methyltransferase-Inhibitor,negative
872,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,MK_0457_tozasertib,2D6-Substrate,negative
873,CC1=CC(=O)C=C2CCC3C4CCC(=O)C4(C)CCC3C12C,Atamestane,-,negative
874,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,Triamcinolone,SUL-Inducer,negative
875,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@@H]3C[C@@H]12,Tetracycline,GST-Inhibitor,negative
876,CNCCCN1c2ccccc2CCc2ccccc21,Desipramine,2E1-Inhibitor,negative
877,OC(CNCC(F)(F)F)COc1cccc2ccccc12,N_trifluoro_ethyl_desisopropyl_propranolol,2D6-Substrate,negative
878,Cn1cnc2c1c(=O)[nH]c(=O)n2C,Theobromine,2E1-Substrate,negative
879,C=CCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_12,3A4-Substrate,negative
880,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Methylergometrine,-,negative
881,Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,Sulfamoxole,-,negative
882,COCc1c(C(C)C)nc(C(C)C)c(C=C[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,Cerivastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
883,CO[C@H]1C=CO[C@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifamycin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
884,CC=O,acetaldehyde,2E1-Substrate,negative
885,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,Clevidipine,2C9-Inhibitor,negative
886,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,Benzydamine,2E1-Substrate,negative
887,CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1,Capravirine,-,negative
888,Cc1cccc(C)c1NC(=O)CN1CCCC1=O,Nefiracetam,-,negative
889,c1ccc(COc2ccc3cccnc3c2)cc1,7_benzyloxy_quinoline,1A2-Substrate,negative
890,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,Repaglinide,-,negative
891,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,lansoprazole_R,2C19-Substrate,negative
892,O=N[O-],Sodium Nitrite,GST-Inhibitor,negative
893,CN(C)N=Nc1[nH]cnc1C(N)=O,Dacarbazine,1A1-Inhibitor,positive
894,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3[C@H]2C1,Praziquantel,P450_HFLA-Substrate,negative
895,C=CC#N,acrylonitrile,2E1-Substrate,negative
896,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,temazepam,2C19-Substrate,negative
897,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,Flurbiprofen,-,negative
898,CN[C@@H](C)Cc1ccccc1OC,Methoxyphenamine,2D6-Substrate,negative
899,CC(C)OC(=O)CCCC=CC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Latanoprost,Solute_carrier_organic_anion_transporter_family_member_2A1-Inhibitor,negative
900,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vindesine,-,negative
901,C[C@@](N)(Cc1ccc(O)c(O)c1)C(=O)O,Methyldopa (levorotatory),GST-Inhibitor,negative
902,CC(CF)NCC(O)COc1cccc2ccccc12,fluoro_propranolol,2D6-Substrate,negative
903,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,Sorafenib,UGT-Inhibitor,negative
904,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21,Zotepine,2D6-Substrate,negative
905,Cc1ccc(S(=O)(=O)NC(=O)NN2C[C@H]3CCC[C@H]3C2)cc1,Gliclazide,-,negative
906,CCCN(CCC)CCc1cccc2c1CC(=O)N2,Ropinirole,2D6-Inhibitor,negative
907,CN1C(=O)[C@](C)(C2=CCCCC2)C(=O)N=C1O,Hexobarbital,-,negative
908,CCN(CC)C(=S)[S-].[Na+],Ditiocarb sodium,-,negative
909,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,Buspirone,P450_HFLA-Substrate,negative
910,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,Melatonin,19A-Inhibitor,negative
911,COP(=S)(OC)SCn1nnc2ccccc2c1=O,azinphosmethyl,2C19-Substrate,negative
912,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,Pleconaril,P450_HFLA-Inducer,negative
913,[Br-],Bromides,Solute_carrier_family_22_member_2-Substrate,negative
914,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Remoxipride,2D6-Substrate,negative
915,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,Cyclobenzaprine,2D6-Substrate,negative
916,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1,Nordazepam,-,negative
917,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,Chlorphenamine,Methyltransferase-Inducer,negative
918,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Dexamethasone,4A11-Inducer,negative
919,CCc1ccc(CCOc2ccc(C[C@@H]3SC(=O)NC3=O)cc2)nc1,Pioglitazone,2D6-Inhibitor,negative
920,Clc1ccc(CO[C@@H](C[C@H]2C=NC=N2)c2ccc(Cl)cc2Cl)cc1,Econazole,19A-Inhibitor,negative
921,CCCCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_butylamphetamine,2D6-Substrate,negative
922,CC(C)[C@H]1CC[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)O)CC1,Nateglinide,P450_HFLA-Substrate,negative
923,Cc1ccc(C(=CCN2CCCC2)c2ccccn2)cc1,Triprolidine,2D6-Inhibitor,negative
924,Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,Cidofovir,Solute_carrier_family_22_member_6-Substrate,negative
925,N=C(N)NC[C@H]1COc2ccccc2O1,Guanoxan,2D6-Substrate,negative
926,CNCc1cc(=O)oc2cc(OC)ccc12,MMAMC,2D6-Substrate,negative
927,O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,Atovaquone,-,negative
928,CCC(=O)O[C@@H]1CC(=O)O[C@@H](C)CC=CC=C[C@@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@H](OC(=O)CC)[C@@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H]1OC,Midecamycin,-,negative
929,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1,Ambroxol,-,negative
930,CCOC(=O)[C@@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,Enalapril,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
931,O=C1C2CCCCC2C(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1,Perospirone,2D6-Substrate,negative
932,CCCN[C@@H]1CCc2nc(N)sc2C1,Pramipexole,-,negative
933,OCCCOc1cccc(CN2CCCCC2)c1,roxatidine_m5,2D6-Substrate,negative
934,Cc1ccc(S(=O)(=O)N(C)c2ccnn2-c2ccccc2)cc1,DMZ,2C19-Substrate,negative
935,OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,Glucose,2E1-Inhibitor,negative
936,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O,Dicoumarol,GST-Inhibitor,negative
937,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,Carvedilol,2E1-Substrate,negative
938,CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1,Talinolol,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
939,c1ccc(C2(N3CCCCC3)CCCCC2)cc1,Phencyclidine,-,negative
940,CC(C)(C)c1ccc([C@@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,Terfenadine,P450_HFLA-Substrate,negative
941,CCC(C)C(=O)OC1CCC=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,Mevastatin,-,negative
942,Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C,Aminophenazone,CP2CI-Substrate,negative
943,C/C=C1/C[C@@H](C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23,senecionine,3A4-Substrate,negative
944,CC(C)NC[C@H](O)c1ccc(O)c(O)c1,Isoprenaline,1A1-Inhibitor,positive
945,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,Indoramin,2D6-Substrate,negative
946,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@@H](NC(=N)N)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O,Dihydrostreptomycin,3A4-Substrate,negative
947,NC(=O)c1c(Cl)c(-c2cccnc2)n2c1CCCC2,CMV_423,2C9-Substrate,negative
948,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1,Ibuprofen,GST-Inducer,negative
949,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,Glibenclamide,-,negative
950,CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O)n2C1,licofelone,2D6-Substrate,negative
951,NC(N)=O,Carbamide,2E1-Inducer,negative
952,CC(=O)c1cc2cccc(OC[C@H](O)CNC(C)C)c2o1,Befunolol,2D6-Substrate,negative
953,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Chenodeoxycholic Acid,GST-Inhibitor,negative
954,COc1ccc2[nH]c3c([N+](=O)[O-])ccc4c3c(nn4CCCN(C)C)c2c1,pyrazolo_acridine,1A2-Substrate,negative
955,C=CCC1([C@H](C)CCC)C(=O)NC(=O)NC1=O,Secobarbital,-,negative
956,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,Dicycloverine,Methyltransferase-Inhibitor,negative
957,CC(N)Cc1ccccc1,amphetamine,2D6-Substrate,negative
958,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,tolterodine,2D6-Substrate,negative
959,CC1(C)O[C@H]2CO[C@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@H]2O1,Topiramate,-,negative
960,C=C1C(=CC=C2CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,Calcitriol,SUL-Inducer,negative
961,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,Norethisterone,P450_HFLA-Substrate,negative
962,C[C@H]1[C@H](NC(=O)C(=NOC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-],Aztreonam,P450_HFLA-Substrate,negative
963,O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,kaempferol,1A2-Substrate,negative
964,C=CCC1(C(C)C)C(=O)NC(=O)NC1=O,Aprobarbital,2B6-Inducer,negative
965,COc1ccc2c(C[n+]3ccccc3)cc(=O)oc2c1,MMPyrC,2D6-Substrate,negative
966,CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C,Mecamylamine,1A1-Inducer,negative
967,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,Diflunisal,UGT-Substrate,negative
968,COc1ccc(CC(C)N)cc1,4_methoxy_amphetamine,2D6-Substrate,negative
969,COC(=O)Nc1nc2cc(Sc3ccccc3)ccc2[nH]1,Fenbendazole,1A2-Inducer,negative
970,CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,Atenolol,3A4-Substrate,negative
971,Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1,Zomepirac,3A4-Substrate,negative
972,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Lisuride,2D6-Substrate,negative
973,Oc1nc2cc(Cl)ccc2o1,Chlorzoxazone,2E1-Inhibitor,negative
974,Cn1c(=O)c2[nH]cnc2n(C)c1=O,Theophylline,1A1-Inhibitor,positive
975,CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,Caspofungin,3A4-Inhibitor,negative
976,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,Topotecan,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
977,CN(C)CC(Oc1ccccc1)Oc1ccccc1,Medifoxamine,-,negative
978,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,Sildenafil,1A1-Inhibitor,positive
979,FC(F)OC(F)(F)[C@H](F)Cl,Enflurane,2E1-Substrate,negative
980,CN1CCC[C@H]1c1cccnc1,Nicotine,2E1-Inducer,negative
981,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,Phenytoin,CP2CI-Substrate,negative
982,Cc1cccc(C)c1OC[C@H](C)N,Mexiletine,2E1-Substrate,negative
983,CN1C2CC[C@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2,tropisetron,2D6-Substrate,negative
984,CCN(CC)C(=O)N1CCN(C)CC1,Diethylcarbamazine,GST-Inducer,negative
985,O=C1CN(N=Cc2ccc([N+](=O)[O-])o2)C(=O)N1,Nitrofurantoin,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
986,Nc1nc([O-])c2c(n1)NCC(CNc1ccc(C(=O)NC(CCC(=O)[O-])C(=O)O)cc1)N2C=O.[Ca+2],Calcium folinate,-,negative
987,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O,Estrone,4A11-Substrate,negative
988,CC1(C)[C@H](C=C(Cl)Cl)[C@H]1C(=O)O[C@H](C#N)c1cccc(Oc2ccccc2)c1,Cypermethrin,1A2-Substrate,negative
989,CC=CC[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,Ciclosporin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
990,CC1=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)C(c2cccc([N+](=O)[O-])c2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1,Efonidipine,-,negative
991,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,Danazol,19A-Inhibitor,negative
992,CNCCC[C@]12CC[C@H](c3ccccc31)c1ccccc12,Maprotiline,2D6-Substrate,negative
993,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Nilotinib,UGT-Inhibitor,negative
994,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,cisapride,2C8-Substrate,negative
995,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,Erlotinib,UGT-Inhibitor,negative
996,Clc1ccc(CS[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,Sulconazole,2E1-Inhibitor,negative
997,CC1=CC(=O)c2ccccc2C1=O,Menadione,2E1-Substrate,negative
998,Cn1c(N)nc2ncc(-c3ccccc3)cc21,2_amino_1_methyl_6_phenylimidazo_4_5_b_pyridine,1A2-Substrate,negative
999,CN(C)CCC[C@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,Citalopram,2E1-Substrate,negative
1000,O=C(OC[C@H](O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,Glafenine,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,negative
1001,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,Losartan,-,negative
1002,Cc1ncsc1CCCl,Clomethiazole,2E1-Inhibitor,negative
1003,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H](O)[C@@]1(C)O,erythromycin,3A4-Substrate,negative
1004,CCCCOC(=O)C(=O)Nc1cccc(-c2nn[nH]n2)c1,Tazanolast,-,negative
1005,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Ergometrine,1A1-Inhibitor,positive
1006,CC(C)c1nc(CN(C)C(=O)N[C@@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,Ritonavir,2E1-Inhibitor,negative
1007,CC(C(=O)c1ccc2c(c1)OCO2)N1CCCC1,MDPPP,2D6-Substrate,negative
1008,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,Pentamidine Isethionate,2D6-Substrate,negative
1009,Cc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,dimemorfan,2D6-Substrate,negative
1010,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,Bexarotene,-,negative
1011,CNC(=O)ON=C(C)SC,Methomyl,-,negative
1012,CNCCCN1c2ccccc2CCc2ccc(Cl)cc21,N_desmethyl_clomipramine,2D6-Substrate,negative
1013,C=CCc1ccc2c(c1)OCO2,safrole,2E1-Substrate,negative
1014,O=S(=O)([O-])[O-],Sodium Sulfate,P450_HP-Inducer,negative
1015,O=C(O)COc1ccc(C(=O)c2ccsc2)c(Cl)c1Cl,tienilic_acid_deriv_3_isomer,2C9-Substrate,negative
1016,Clc1ccc2nsnc2c1NC1=NCCN1,Tizanidine,1A2-Substrate,negative
1017,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,Benazepril,Aldosterone_synthase_ALDOS_Aldosterone_synthesizing_enzyme_Steroid_18_hydroxylase-Inhibitor,negative
1018,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],Glyceryl Trinitrate,GST-Inducer,negative
1019,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,Pefloxacin,-,negative
1020,CCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)CC=CC=C[C@H](OC(C)=O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(C)=O,Miocamycin,3A4-Inhibitor,negative
1021,c1ccc2[nH]c(-c3cscn3)nc2c1,Tiabendazole,-,negative
1022,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,Riboflavin (vit B2),ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
1023,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,Bosentan,Sodiumbile_acid_cotransporter-Inhibitor,negative
1024,CC(NCCCOc1cccc2ccccc12)C(F)(F)F,deshydroxy_trifluoro_propranolol,2D6-Substrate,negative
1025,NC[C@@H](O)c1ccc(O)c(O)c1,Norepinephrine,19A-Inhibitor,negative
1026,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,Cilostazol,2D6-Substrate,negative
1027,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,Clomipramine,GST-Inhibitor,negative
1028,CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,indiplon,1A2-Substrate,negative
1029,COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC,Oxypertine,Canalicular_multispecific_organic_anion_transporter_2-Inducer,negative
1030,C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1,Bupropion,2E1-Substrate,negative
1031,Cc1cc2ccccc2c2ccc3ccccc3c12,5_methylchrysene,2E1-Substrate,negative
1032,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,Hydromorphone,2D6-Substrate,negative
1033,CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3,Apomorphine,SUL-Substrate,negative
1034,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,Meloxicam,-,negative
1035,N=C(N)NC(=N)NCCc1ccccc1,Phenformin,2D6-Substrate,negative
1036,CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1,ibuprofen_R,2C9-Substrate,negative
1037,CC[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,Phenprocoumon,-,negative
1038,C[C@H]1O[C@@H]1P(=O)(O)O,Fosfomycin,GST-Substrate,negative
1039,CN1CCCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,Homochlorcyclizine,-,negative
1040,CSCCC(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CC(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)O)C(C)O,Glucagon,GST-Inhibitor,negative
1041,CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1,Difloxacin,-,negative
1042,NNc1nnc(NN)c2ccccc12,Dihydralazine,-,negative
1043,CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,Eprosartan,-,negative
1044,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,Cefalexin,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
1045,CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1,rosiglitazone_R,2C9-Substrate,negative
1046,CC1=CC[C@H]2[C@@H](C1)C2(C)C,delta_3_carene,2D6-Substrate,negative
1047,ClC(Cl)Cl,Chloroform,2E1-Substrate,negative
1048,CC(C)(Oc1ccc([C@H]2CC2(Cl)Cl)cc1)C(=O)O,Ciprofibrate,4A11-Inducer,negative
1049,CNC(=O)Oc1cccc2c1OC(C)(C)C2,carbofuran,2D6-Substrate,negative
1050,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vinblastine,2D6-Substrate,negative
1051,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,Dextromethorphan,2E1-Substrate,negative
1052,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,Methylprednisolone,-,negative
1053,CN[C@@H](C)[C@H](O)c1ccccc1,Ephedrin,SUL-Substrate,negative
1054,CCN[C@H](C)Cc1ccc2c(c1)OCO2,MDE_R,2E1-Substrate,negative
1055,C[S+](CC[C@H](N)C(=O)[O-])C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,Ademetionine,2E1-Inhibitor,negative
1056,O=c1c2ccccc2nc2n1CCc1c-2[nH]c2ccccc12,rutaecarpine,2E1-Substrate,negative
1057,CCC1C2CC3C4N(C)c5ccccc5C45CC(C2C5O)N3C1O,Ajmaline,2D6-Inhibitor,negative
1058,CN1CCC[C@H](n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,Azelastine,2E1-Inhibitor,negative
1059,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C,Tinidazole,19A-Inhibitor,negative
1060,CCCC(CCC)C(=O)O,Valproic Acid,4A11-Inducer,negative
1061,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,Eletriptan,2D6-Substrate,negative
1062,COc1ccc(CCN(C)CCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,verapamil_R,2C8-Substrate,negative
1063,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Ropivacaine,2D6-Substrate,negative
1064,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,Betamethasone,-,negative
1065,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,Rofecoxib,GST-Inducer,negative
1066,COc1cc2c(cc1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,Tetrabenazine,2D6-Inhibitor,negative
